Reduce Failure and Achieve Meaningful Results
in Cardiovascular Devices Prior to Prototype
WHITEPAPER
With more than 30% of all deaths attributed to cardiovascular disease, the healthcare
industry invests massively in disease prevention, treatment, and efforts to shorten the
recovery period. But the extensive in vitro and in vivo testing required to ensure patient
safety inevitably slows down cardiovascular device innovation.
